Form 4: LeMaitre Vascular Director Martha Shadan Reports Stock Acquisition and Dividend Equivalent Rights Release
SEC Form 4 Filing
Director Martha Shadan acquired 204 shares of LeMaitre Vascular common stock upon settlement of a Performance Share Unit (PSU) award and released dividend equivalent rights, as reported in a recent SEC Form 4 filing.
Summary
- On February 28, 2025, Martha Shadan, a director of LeMaitre Vascular, acquired 204 shares of common stock upon the settlement of a Performance Share Unit (PSU) award.
- The PSU award was granted on December 8, 2023, and vests in installments.
- Shadan also acquired 1 share upon the release of dividend equivalent rights.
- Following these transactions, Shadan directly owns 1,936 shares of LeMaitre Vascular common stock.
- The filing also includes a Limited Power of Attorney, effective December 5, 2024, granting certain individuals the authority to execute SEC forms on Shadan's behalf.
Sentiment
Score: 7
Explanation: The document reflects standard insider trading disclosures, suggesting a neutral to slightly positive sentiment as it indicates continued director ownership in the company.
Positives
- The acquisition of shares through PSU settlement and dividend equivalent rights release indicates continued alignment of the director's interests with the company's performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which is a common practice for publicly traded companies like LeMaitre Vascular. It provides transparency to investors regarding the ownership and trading activities of the company's directors.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice in corporate governance, ensuring transparency and preventing potential conflicts of interest.
- Companies like Medtronic, Boston Scientific, and Edwards Lifesciences also have similar reporting requirements for their executives and directors.
Stakeholder Impact
- The disclosure provides transparency to shareholders regarding insider transactions.
- The transactions themselves have a minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| December 5, 2024 | Date of Limited Power of Attorney execution. |
| December 8, 2023 | Date of PSU award grant. |
| February 28, 2025 | Date of stock acquisition and dividend equivalent rights release. |
| March 4, 2025 | Date of signature on the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.